COVID-19 Early Treatment Fund (CETF)

Created to ensure the rapid and successful completion of outpatient clinical trials that lead to effective early treatments for #COVID19, using existing drugs.

[COVID-19 Early Treatment Fund (CETF) @treatearly]

Critically-important research on #fluvoxamine as a promising early treatment for #COVID19 continues! Washington University in St. Louis has opened a nationwide, contactless clinical trial, enabling patients to participate from home. Learn more: https://t.co/BBhh2MMpRe

[COVID-19 Early Treatment Fund (CETF) @treatearly]

Another tragic example of why researching a cheap, generic drug to treat early #Covid symptoms is still urgent to fight this #pandemic globally.

“Despite the efforts to save money for vaccines, by the end of April the country had fully vaccinated only about 362,000, or 1.2%"

[The Wall Street Journal @WSJ]

"The disease has become unpredictable, and we are struggling to understand it." As India’s Covid-19 surge has swept into Nepal, hospitals are reporting an overwhelming number of severe cases and similar shortages of beds, oxygen and ventilators. https://t.co/7cVk1XBgAA

[Angela Reiersen, MD, MPE @AngelaReiersen]

I'm discussing “Fluvoxamine Quick Update” with 2nd Time Around. Today, May 10 at 5:00 PM CDT on @clubhouse. Join us! https://t.co/xOc9ayrNzp

[COVID-19 Early Treatment Fund (CETF) @treatearly]

Countries are being devastated by new waves of #COVID19. Repurposing a drug like #fluvoxamine for early treatment has the potential save lives around the world, but more data is needed. If you have Covid, consider the Stop Covid Trial and help solve the global crisis.

[The Wall Street Journal @WSJ]

Driven by slow vaccine rollouts, new variants and pandemic fatigue, Covid-19 case rates across the globe are at their highest levels since the start of the health crisis. “There’s still a long way for this pandemic to run.” https://t.co/v1QklSCHeR

[COVID-19 Early Treatment Fund (CETF) @treatearly]

“However, given the current crisis, which is expected to worsen before a vaccine takes effect, one wonders if the FLV evidence in COVID-19 is strong enough to consider a change in practice guidelines, to even more quickly accumulate data on outcomes in COVID-19 patients”

[Angela Reiersen, MD, MPE @AngelaReiersen]

Our full paper on possible mechanisms of fluvoxamine in treating COVID19 has now been published in @FrontiersIn Pharmacology. https://t.co/B000BQCanI

[Parsemus Foundation @Parsemus]

Are you 30+ and just got #COVID19? You may be eligible to participate in a nationwide #treatment trial for a medication that may protect people with #COVID from getting sick. Details here. https://t.co/rPZvE84yYP

[COVID-19 Early Treatment Fund (CETF) @treatearly]

A sobering reminder that we are not out of the woods yet and promising early #COVID19 treatments like #fluvoxamine can still help many sick people and also relieve our healthcare workers who have been overtaxed for too long.

[Rachel Maddow @maddow]

"Stasik said her emergency department has been at capacity for three weeks straight.

“Every unit was full. Every unit had every bed full, including our ICU.

“We had nowhere to go. We had nowhere to put people."
https://t.co/Z8ejS1EWiH

[Dr. Sanjay Gupta @drsanjaygupta]

Thanks @DavidFajgenbaum. A fascinating conversation about how to go about identifying good (often cheap) candidates for “repurposed” drugs — to treat COVID.

[Ezra Klein @ezraklein]

"Following the science" and "following the existing evidence" are not the same things, but politicians and regulators talk like they are.

Science can’t tell you what it does not yet know, and the virus spreads faster than our knowledge. https://t.co/vdvEhd0cPK

[Esther Wei-Yun Landhuis @elandhuis]

Outpatient #COVID19 drugs could already be on pharmacy shelves, but testing them takes time and $$ that gov't & pharma will rarely spend. Thanks to philanthropy (eg @treatearly @Parsemus), studies are in progress & should yield answers soon. 1/n
https://t.co/2YJgpxITnz

[COVID-19 Early Treatment Fund (CETF) @treatearly]

CETF founder @stkirsch writes about the long and frustrating battle over the #FDA authorizing affordable, repurposed drugs for #COVID early treatment and how better methods to test, approve and distribute those drugs will save lives.

[Mercury News @mercnews]

Opinion: How we can lower COVID hospitalization, fatality rates https://t.co/cXxKcPElTi

[Inside Philanthropy @InsidePhilanthr]

Paul Karon returns to discuss Steve Kirsch’s COVID-19 Early Treatment Fund, and philanthropy’s puzzling silence, even as a possible breakthrough medicine is being tested. https://t.co/223r4WyoOn

@stkirsch

[COVID-19 Early Treatment Fund (CETF) @treatearly]

"Researchers believe Fluvoxamine could play a critical role in keeping millions of COVID-19 patients who haven’t yet been vaccinated out of the hospital in the coming years."

https://t.co/ELnwJZ3c3x

[Antidote @antidote_me]

One potential treatment avenue for #COVID19 involves repurposing approved drugs. Find out if you’re a match for the @treatearly #fluvoxamine study recently featured on @60Minutes: https://t.co/X1PtU1yxvF

[Angela Reiersen, MD, MPE @AngelaReiersen]

I love this extra @60Minutes interview segment with @NIHDirector Francis Collins. I agree we could have used a better plan for testing existing drugs at the start of the pandemic. https://t.co/OHPZoc4jMJ

[COVID-19 Early Treatment Fund (CETF) @treatearly]

@DSeftel and @boulware_dr report new data showing that #fluvoxamine can prevent people from getting seriously ill with #covid. Results come from real-world use to treat workers at @GGFracing. Those who opted to take, none got sicker.
https://t.co/B42OnPJIJR

[Skoll Foundation @SkollFoundation]

Skoll grantee @treatearly and their groundbreaking work with fluvoxamine #COVID19 treatment was profiled by @60Minutes showing that the U.S. drug-approval system, particularly during a pandemic, can be more efficient. https://t.co/UP1MqfayjZ

[COVID-19 Early Treatment Fund (CETF) @treatearly]

So grateful to @60minutes for shining a spotlight on #fluvoxamine as a promising early treatment for #COVID19. If you or someone you know has been recently diagnosed with Covid, @WashUMed’s nationwide, contactless clinical trial is open for enrollment. https://t.co/vo5Og8R2Vv

[60 Minutes @60Minutes]

“You cannot influence a virus that is as wily and as wicked as COVID with a fluke,” says Dr. David Seftel after none of his COVID patients who took Fluvoxamine deteriorated. Currently, the drug is being tested in a larger trial. https://t.co/7Et63U4LhO

[COVID-19 Early Treatment Fund (CETF) @treatearly]

60 Minute debrief with CETF Medical Advisor Dr. Lisa Danzig. Please join!

[Kat Jong, MD @jong_kat]

@AngelaReiersen @EricLenze2 @CalineMattar @statprof @avidan_michael @drrodebaugh @WUSTLmed @WUICTS @60Minutes @CBS 📺⏱Post- “60 Minutes” Discussion⏱ (fluvoxamine/COVID19)” with @AngelaReiersen, Lisa Danzig, Farid Jalali, @drallysonocean, @normannguuu, @slenzepsych, Ginger Nicol, and Virtual Grand Rounds. Today, Mar 7 at 7:00 PM PST on @joinclubhouse. Join us! https://t.co/OWUtbnKgRM

[Daniel Kraft, MD @daniel_kraft]

Promising drug repurposing for outpatient Rx of #COVID19:

The SSRI #Fluvoxamine demonstrates significant promise in Phase 2 trials, being featured on @60Minutes

Kudos to @stkirsch, @TreatEarly & the 'Stop-Covid Study' @WUSTLmed https://t.co/xR18hoIDlN

https://t.co/bwhtBpcBDi

[60 Minutes @60Minutes]

As more and more people get vaccinated against COVID, scientists are still searching for solutions to keep COVID patients from deteriorating. Tonight, a report on one possible early treatment. https://t.co/iUMALTZGEk